Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study to Investigate the Efficacy, Mechanism of Action, Pharmacokinetics, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 as Monotherapy in Patients With Gastroesophageal Reflux Disease (GERD).

Trial Profile

A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study to Investigate the Efficacy, Mechanism of Action, Pharmacokinetics, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 as Monotherapy in Patients With Gastroesophageal Reflux Disease (GERD).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raseglurant (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Sponsors Addex Therapeutics

Most Recent Events

  • 23 Oct 2010 Results presented at the 18th United European Gastroenterology Week.
  • 06 May 2010 Results of the patients evaluated mechanisitically were presented at Digestive Disease Week 2010.
  • 05 May 2010 Results were presented at Digestive Disease Week 2010

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top